Peptides · Peptide comparison
Chonluten vs LL-37
Bronchopulmonary tripeptide bioregulator (Glu-Asp-Gly) that restores respiratory epithelial function through DNA minor groove binding at ATTTC sequences, induces TNF tolerance in alveolar macrophages reducing inflammatory cytokines by up to 6-fold, and normalizes bronchial mucosa differentiation markers in aging lung tissue
Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers
- Immune
- Immune
At a glance
Quick comparison
Efficacy
Benefit ratings
Respiratory Tissue Repair
Lung Inflammation Control
Age-Related Lung Protection
Wound Healing
Fighting Infections
Immune Boost
Technical data
Compound specifications
Chonluten
- Molecular formula
- C11H17N3O8
- Molecular weight
- 319.27 g/mol
- Half-life
- Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to bronchopulmonary gene expression; metabolized to constituent amino acids
- Bioavailability
- Absorbed via intestinal peptide transporters (PepT1) in oral formulation with enteric coating; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short tripeptide structure
- CAS number
- 75007-24-8
LL-37
- Molecular formula
- C205H340N60O53
- Molecular weight
- 4,493.26 Da
- Half-life
- Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
- Bioavailability
- Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery
- CAS number
- 154947-66-7
Protocols
Dosing compared
Chonluten
Subcutaneous
- 5-10 mgOnce daily · 10-20 days per courseFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]
Oral
- 1-2 capsules1-2 times daily with meals · 10-30 day course, repeated 2-3 times per yearThe oral capsule plan used in practice for this bronchopulmonary peptide supplement. [6]
LL-37
Topical
- 0.5 mg/mL gelTwice weekly · 4 weeksLowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].
- 1.6 mg/mL gelTwice weekly · 4 weeksMid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].
Applications
Best suited for
Chonluten
- Respiratory health restoration in aging individuals with declining lung function
- Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective therapy for lung tissue preservation in elderly populations
- Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
LL-37
- Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
- LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
- Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
- LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3][5].
- Anti-biofilm strategies for chronic wound infections and medical device-associated infections
- LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
- Boosting innate immune defense in immunocompromised or aging individuals
- LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].
Safety profile
Side effects
Chonluten
Common
- Injection site reaction
- Mild fatigue
- Transient respiratory changes
- Mild headache
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
LL-37
Common
- Local site irritation
- Transient stinging or burning
- Mild perilesional erythema
- Increased wound exudate
Uncommon
- Allergic contact reaction
Serious
- Hemolytic activity at systemic concentrations
Research status
Safety & evidence
Chonluten
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, glycine)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active pulmonary infections requiring immediate medical treatment
- Severe immunosuppression without medical supervision — immunomodulatory effects may be unpredictable
LL-37
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, [2] conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.
Contraindications
- Known hypersensitivity to cathelicidin peptides or formulation components
- Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
- Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
- Severe renal impairment — peptide clearance may be altered
Decision guide
Which is right for you?
Chonluten
Choose Chonluten if…
- Respiratory health restoration in aging individuals with declining lung function
- Chronic bronchopulmonary conditions requiring tissue-level regenerative support
- Comprehensive Khavinson bioregulator protocols targeting respiratory and immune function
- Geroprotective therapy for lung tissue preservation in elderly populations
LL-37
Choose LL-37 if…
- Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers
- Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)
- Anti-biofilm strategies for chronic wound infections and medical device-associated infections
- Boosting innate immune defense in immunocompromised or aging individuals